Skip to content

NEVRO CORP

Delisted

CIK 1444380fmd_01CM0EEJTTP6MD4GM9AV11XJ8JManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard

Coverage: Jan 01, 2012 to Dec 31, 2024, 49 periods

Income Statement · Annual · Millions · USD
Line itemFY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Total revenues70229327387390362387406425409
Cost of revenue287599114122112121130135139
Net interest income––––––––––
Gross profit41153228273268250266276290270
Realized investment gains (losses)00––––––––
Research and development21343848594648535452
Selling, general and administrative82142220267306267309322335310
Total operating expenses104176257315365313377270389396
Operating income(62)(23)(30)(42)(96)(63)(111)6(99)(126)
Interest expense3610101122206827
Interest and investment income123563141413
Other non-operating income (expense)(2)(1)1(1)(1)(0)(1)1(1)(0)
Income before taxes(66)(30)(35)(48)(102)(82)(131)4(98)(112)
Income tax expense12112111(6)1
Net income from continuing operations(67)(32)(37)(49)(104)(83)(131)3(92)(113)
Net income(67)(32)(37)(49)(104)(83)(131)3(92)(113)
Net income to common shareholders(67)(32)–––(83)(131)3(92)(113)
NEVRO CORP financial statements · FinancialMD